By continuing to use our site, you agree to our Terms of Use and Privacy Policy. You can learn more about how we use cookies by reviewing our Privacy Policy.

I Agree
Home > Focus On Rare

OUR THERAPEUTIC DEVELOPMENT PROGRAMS

Lumos Pharma is a late-stage clinical biopharmaceutical company committed to identifying, developing and commercializing life-changing therapies for patients and families.

The Company’s pipeline features development programs in rare diseases associated with growth hormone deficiencies.

Lumos Pharma plans to expand its pipeline through strategic partnerships with those who share our mission of bringing innovative medicines to improve the lives of patients and families living with rare diseases.

LUM-201

  • Also known as ibutamoren, LUM-201 is an orally administered small molecule that promotes the secretion (secretagogue) of Growth Hormone (GH) from the pituitary gland.1
  • LUM-201 acts as an agonist of the GH Secretagogue Receptor to stimulate GH release.2
  • LUM-201 has been observed to increase the amplitude of endogenous pulsatile GH secretion in humans, which mimics the natural pattern of GH secretion.3,4
  • It has been studied in more than 1300 patients, both adult and pediatric, and was generally well tolerated.*
  • Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD met all primary and secondary endpoints.

*IMPORTANT SAFETY INFORMATION: LUM-201 has a favorable investigational safety profile to date. LUM-201 was generally well-tolerated in children with the most commonly reported adverse events being increased appetite, pain in extremity and arthralgia. No meaningful safety signals have been observed in laboratory values, adverse events data, or in EKG values to date- Phase 2 Trials OraGrowtH210 and 212 Safety Data as of March 2024 cut-off date.

Learn More About PGHD

 

References

  1. Patchett A.A. et al, Design and Biological Activities of L-163,191 (MK-0677): A Potent, Orally Active Growth Hormone Secretagogue, Proc Natl Acad Sci, 1995, 92:7001-7005
  2. Howard A.D. et al, A Receptor in Pituitary and Hypothalamus that Functions in Growth Hormone Release, Science, 1996, 273:974-977
  3. Nass R. et al, Effects of an Oral Ghrelin Mimetic on Body Composition and Clinical Outcomes in Healthy Older Adults, Ann Intern Med, 2008, 149:601-611
  4. Chapman I.M. et al, Oral Administration of Growth Hormone (GH) Releasing Peptide-Mimetic MK-677 Stimulates the GH/Insulin-Like Growth Factor-I Axis in Selected GH-Deficient Adults, J Clin Endocrinol Metab, 1997, 82(10):3455-3463